ಬ್ರೈನ್ ಟ್ಯೂಮರ್
Short Versus Long-term Levetiracetam in Brain Tumors
ಎಲ್ಲಿಗೆ ಹೋಗಬೇಕು
ಈ trial ಗೆ 1 ಆಸ್ಪತ್ರೆ ರೋಗಿಗಳನ್ನು ಸೇರಿಸಿಕೊಳ್ಳುತ್ತಿದೆ.
ರಿಜಿಸ್ಟ್ರಿ ಸಾರಾಂಶ (ತಾಂತ್ರಿಕ)
Levetiracetam is the commonly preferred anti-seizure medicine in patients with brain tumors. This drug has reduced the risk of seizure events occurring but is associated with a risk of side effects such as increased headache, drowsiness, loss of muscle coordination, and psychological challenges in patients. In patients undergoing appropriate treatment for brain tumors and controlled of seizures in the initial few months of levetiracetam, the chance of further seizures is relatively low. The optimal duration to give levetiracetam is not well defined for these patients, and currently as standard…
ಪ್ರಾಯೋಜಕರು: ಟಾಟಾ ಮೆಮೋರಿಯಲ್ ಸೆಂಟರ್
ClinicalTrials.gov ನಲ್ಲಿ NCT06442748
ನೋಂದಣಿಯಲ್ಲಿ ಕೊನೆಯದಾಗಿ ಅಪ್ಡೇಟ್ 13 ಫೆಬ್ರವರಿ 2026 · ನಾವು ಓದಿದ್ದು 20 ಅಕ್ಟೋಬರ್ 2026